Table II.
Association of XRCC3, RAD51, and NBN SNPs with risk for osteosarcoma.
| Gene | Polymorphism | Genotype | Controls (%) | All patients | Patients <30 years | ||||
|---|---|---|---|---|---|---|---|---|---|
| Cases (%) | OR (95% CI) | P | Cases (%) | OR (95% CI) | P | ||||
| XRCC3 | rs1799794 A>G c.-316A>G |
AA | 247 (66.2) | 47 (59.5) | 1.29 (0.78–2.14) | 0.315 | 27 (56.3) | 1.53 (0.83–2.80) | 0.175 |
| AG+GG | 126 (33.8) | 31 (39.2) | 21 (43.8) | ||||||
| rs861539 C>T p.Thr241Met |
CC | 153 (41.0) | 39 (49.4) | 0.71 (0.44–1.16) | 0.174 | 27 (56.3) | 0.54 (0.30–0.99) | 0.047 | |
| CT+TT | 220 (59.0) | 40 (50.6) | 21 (43.8) | ||||||
| RAD51 | rs1801320 G>C c.-98G>C |
GG | 304 (81.5) | 69 (87.3) | 0.58 (0.27–1.21) | 0.143 | 41 (85.4) | 0.65 (0.26–1.58) | 0.337 |
| GC+CC | 69 (18.5) | 9 (11.4) | 6 (12.5) | ||||||
| rs1801321 G>T c.-61G>T |
GG | 133 (35.7) | 25 (31.6) | 1.20 (0.71–2.01) | 0.497 | 18 (37.5) | 0.92 (0.50–1.72) | 0.802 | |
| GT+TT | 240 (64.3) | 54 (68.4) | 30 (62.5) | ||||||
| rs12593359 T>G c.*502T>G |
TT | 103 (27.6) | 22 (27.8) | 0.99 (0.58–1.70) | 0.966 | 12 (25.0) | 1.14 (0.57–2.29) | 0.702 | |
| TG+GG | 270 (72.4) | 57 (72.2) | 36 (75.0) | ||||||
| NBN | rs1805794 G>C p.Glu185Gln |
GG | 33 (8.8) | 11 (13.9) | 0.60 (0.29–1.25) | 0.170 | 9 (18.8) | 0.42 (0.19–0.94) | 0.036 |
| GC+CC | 340 (91.2) | 68 (86.1) | 39 (81.3) | ||||||
| rs709816 C>T p.Asp399= |
CC | 139 (37.3) | 29 (36.7) | 1.02 (0.62–1.69) | 0.926 | 18 (37.5) | 0.99 (0.53–1.84) | 0.975 | |
| CT+TT | 234 (62.7) | 50 (63.3) | 30 (62.5) | ||||||
| rs1063054 A>C c.*1209A>C |
AA | 163 (43.7) | 38 (48.1) | 0.78 (0.47–1.27) | 0.315 | 22 (45.8) | 0.81 (0.44–1.51) | 0.508 | |
| AC+CC | 210 (56.3) | 38 (48.1) | 23 (47.9) | ||||||